- Home
- VIGL vs CPHC Comparison
VIGL vs CPHC Comparison
Compare VIGL & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- CPHC
- Stock Information
- Founded
- VIGL 2020
- CPHC 1994
- Country
- VIGL United States
- CPHC United States
- Employees
- VIGL N/A
- CPHC N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- VIGL Health Care
- CPHC Consumer Discretionary
- Exchange
- VIGL Nasdaq
- CPHC Nasdaq
- Market Cap
- VIGL 95.2M
- CPHC 94.6M
- IPO Year
- VIGL 2022
- CPHC 1994
- Fundamental
- Price
- VIGL $1.70
- CPHC $20.89
- Analyst Decision
- VIGL Buy
- CPHC
- Analyst Count
- VIGL 6
- CPHC 0
- Target Price
- VIGL $16.60
- CPHC N/A
- AVG Volume (30 Days)
- VIGL 387.1K
- CPHC 2.5K
- Earning Date
- VIGL 11-07-2024
- CPHC 11-07-2024
- Dividend Yield
- VIGL N/A
- CPHC 1.34%
- EPS Growth
- VIGL N/A
- CPHC N/A
- EPS
- VIGL N/A
- CPHC 0.94
- Revenue
- VIGL N/A
- CPHC $62,111,814.00
- Revenue This Year
- VIGL N/A
- CPHC N/A
- Revenue Next Year
- VIGL N/A
- CPHC N/A
- P/E Ratio
- VIGL N/A
- CPHC $22.19
- Revenue Growth
- VIGL N/A
- CPHC 0.13
- 52 Week Low
- VIGL $1.60
- CPHC $17.10
- 52 Week High
- VIGL $6.06
- CPHC $30.25
- Technical
- Relative Strength Index (RSI)
- VIGL 23.30
- CPHC 52.41
- Support Level
- VIGL $1.60
- CPHC $19.92
- Resistance Level
- VIGL $2.46
- CPHC $20.95
- Average True Range (ATR)
- VIGL 0.16
- CPHC 1.04
- MACD
- VIGL -0.02
- CPHC -0.08
- Stochastic Oscillator
- VIGL 11.63
- CPHC 39.18
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.